Shares of Agilent Technologies, Inc. (NYSE:A – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-two ratings firms that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $181.45.
A has been the topic of a number of recent research reports. HSBC lifted their price target on Agilent Technologies from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, September 1st. TD Cowen boosted their target price on shares of Agilent Technologies from $180.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. Stifel Nicolaus upped their price target on shares of Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Finally, Barclays raised their price target on shares of Agilent Technologies from $175.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th.
Check Out Our Latest Stock Analysis on A
Agilent Technologies Price Performance
Agilent Technologies (NYSE:A – Get Free Report) last issued its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the business posted $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts anticipate that Agilent Technologies will post 6.20 earnings per share for the current year.
Agilent Technologies Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 28th. Investors of record on Tuesday, October 6th were paid a $0.2550 dividend. The ex-dividend date of this dividend was Tuesday, October 6th. This represents a $1.02 annualized dividend and a dividend yield of 0.6%. Agilent Technologies’s payout ratio is currently 20.08%.
Insiders Place Their Bets
In related news, Director Mikael Dolsten sold 634 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $151.38, for a total value of $95,974.92. Following the completion of the sale, the director directly owned 4,924 shares in the company, valued at $745,395.12. This represents a 11.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of A. State Street Corp grew its position in shares of Agilent Technologies by 1.0% in the 3rd quarter. State Street Corp now owns 12,979,038 shares of the medical research company’s stock valued at $2,236,418,000 after buying an additional 124,808 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Agilent Technologies by 2.7% in the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company’s stock worth $990,206,000 after acquiring an additional 198,253 shares during the period. Deutsche Bank AG boosted its holdings in Agilent Technologies by 17.1% in the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock valued at $930,957,000 after acquiring an additional 1,024,516 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after acquiring an additional 2,440,360 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in Agilent Technologies in the second quarter valued at approximately $260,101,000.
Agilent Technologies Company Profile
Agilent Technologies develops and supplies instruments, software, services and consumables used in laboratories and manufacturing operations. Its offerings support applications in life sciences, diagnostics, chemical analysis, food safety, environmental testing and pharmaceutical research. The company serves customers worldwide, including pharmaceutical and biotechnology companies, clinical and academic laboratories, and organizations in the chemical, energy and food industries. Its services include laboratory equipment maintenance, technical support and related workflow solutions.
Featured Articles
- Five stocks we like better than Agilent Technologies
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
